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Abstract—This article is a proceeding sur-
vey (deepening a talk given by the first author
at the BioMath 2019 International Conference
on Mathematical Models and Methods, held
in Będlewo, Poland) of mathematical models
of cancer and healthy cell population adaptive
dynamics exposed to anticancer drugs, to
describe how cancer cell populations evolve
toward drug resistance.
Such mathematical models consist of par-
tial differential equations (PDEs) structured
in continuous phenotypes coding for the ex-
pression of drug resistance genes; they in-
volve different functions representing targets
for different drugs, cytotoxic and cytostatic,
with complementary effects in limiting tu-
mour growth. These phenotypes evolve con-
tinuously under drug exposure, and their fate
governs the evolution of the cell population
under treatment. Methods of optimal control
are used, taking inevitable emergence of drug
resistance into account, to achieve the best
strategies to contain the expansion of a tu-
mour.
This evolutionary point of view, which re-
lies on biological observations and resulting
modelling assumptions, naturally extends to
questioning the very nature of cancer as evo-
lutionary disease, seen not only at the short
time scale of a human life, but also at the
billion year-long time scale of Darwinian evo-
lution, from unicellular organisms to evolved
multicellular organs such as animals and man.
Such questioning, not so recent, but recently
revived, in cancer studies, may have conse-
quences for understanding and treating can-
cer.
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Some open and challenging questions may
thus be (non exhaustively) listed as:
• May cancer be defined as a spatially lo-
calised loss of coherence between tissues
in the same multicellular organism, ‘spa-
tially localised’ meaning initially starting
from a given organ in the body, but also
possibly due to flaws in an individual’s
epigenetic landscape such as imperfect
control of differentiation genes?
• If one assumes that “The genes of cellular
cooperation that evolved with multicel-
lularity about a billion years ago are
the same genes that malfunction in can-
cer.” (Davies and Lineweaver, 2011), how
can these genes be systematically investi-
gated, looking for zones of fragility - that
depend on individuals - in the ‘tinker-
ing’ (F. Jacob, 1977) evolution is made of,
tracking local defaults of coherence?
• What is such coherence made of and
to what extent is the immune system
responsible for it (the self and differen-
tiation within the self)? Related to this
question of self, what parallelism can be
established between the development of
multicellularity in different species pro-
ceeding from the same origin and the
development of the immune system in
these different species?
Keywords-Cell population dynamics; struc-
tured models; Darwinian evolution; drug-
induced drug resistance; cancer therapeutics;
optimal control
I. Introduction: Motivation from and
focus on drug resistance in cancer
Slow genetic mechanisms of ‘the great evolu-
tion’ that has designed multicellular organisms,
together with fast reverse evolution on smaller
time windows, at the scale of a human disease,
may explain transient or established drug re-
sistance. This will be developed around the so-
called atavistic hypothesis of cancer.
Plasticity in cancer cells, i.e., epigenetic [30],
[64] (much faster than genetic mutations, and
reversible) propension to reversal to a stem-
like, de-differentiated phenotypic status, result-
ing in fast adaptability of cancer cell popula-
tions, makes them amenable to resist abrupt
drug insult (high doses of cytotoxic drugs, ion-
ising radiations, very low oxygen concentrations
in the cellular medium) as response to cellular
stress.
Intra-tumour heterogeneity with respect to
drug resistance potential, meant here to model
between-cell phenotypic variability within can-
cer cell populations, is a good setting to rep-
resent continuous evolution towards drug re-
sistance in tumours. This is precisely what is
captured by mathematical (PDE) models struc-
turing cell populations in relevant phenotypes,
relevant here meaning adapted to describe an
environmental situation that is susceptible to
abrupt changes, such as introduction of a deadly
molecule in the environment. Beyond classical
(in ecology) viability and fecundity, reversible
plasticity for cancer cell populations may also
be set as one of such phenotypes.
Such structured PDE models have the advan-
tage of being compatible with optimal control
methods for the theoretical design of optimised
therapeutic protocols involving combinations of
cytotoxic and cytostatic (and later possibly epi-
genetic [89]) treatments. The objective function
of such optimisation procedure being chosen as
minimising a cancer cell population number, the
constraints will consist of minimising unwanted
toxicity to healthy cell populations. The innova-
tion in this point of view is that success or failure
of therapeutic strategies may be evaluated by a
mathematical looking glass into the hidden core
of the cancer cell population, in its potential of
adaptation to cellular stress.
The poor understanding of the determinants
of drug resistance in cancer at the epigenetic
level thus far, and the unexplained failure - or
partial failure - of initially promising treatments
such as targeted therapies and immunotherapies
make it mandatory, from our point of view, to
examine cancer, its evolution and its treatment
at the level of a whole multicellular organism
that - locally, to begin with - progressively lacks
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its within- and between-tissue cohesion.
II. Biological background
A. The many facets of drug resistance in cancer
Drug resistance is a phenomenon common
to various therapeutic situations in which an
external pathogenic agent is proliferating at the
expense of the resources of an organism: an-
tibiotherapy, virology, parasitology, target pop-
ulations are able to develop drug resistance
mechanisms (e.g., expression of β-lactamase in
bacteria exposed to amoxicillin). In cancer, there
is in general no external pathogenic agent (even
though one may have favoured the disease) and
the target cell populations share much of their
genome with the host healthy cell population,
making overexpression of natural defence phe-
nomena easy (e.g., ABC transporters in cancer
cells). Note that drug resistance (and resistance
to radiotherapy) is one of the many forms of
fast resistance to cellular stress, possibly coded
in ‘cold’, i.e., strongly preserved throughout evo-
lution, rather than in ‘hot’, i.e., mutation-prone,
genes [107].
At the molecular level in a single cell (that is
per se insufficient to explain the emergence of
drug resistance), overexpression of ABC trans-
porters, of drug processing enzymes, decrease
of drug cellular influx, etc. [38] are relevant to
describe endpoint molecular resistance mecha-
nisms. At the cell population level, representing
drug resistance by an abstract continuous vari-
able x standing for the level of expression of a
resistance phenotype (in evolutionary game the-
ory [4]: a strategy of the population) is adapted
to describe continuous evolution from total sen-
sitivity (x = 0) towards total resistance (x = 1).
Is such evolution towards drug resistance due
to sheer Darwinian selection of the fittest by
mutations in differentiation at cell division or,
at least partially, due to phenotype adaptation
in individual cells? This is by no means clear
from biological experiments. In particular, it has
been shown in [88] that emergence of drug re-
sistance may be totally reversible, and, further-
more, that it may be completely dependent on
the expression and activity of epigenetic control
drugs (DNA methyltransferases). This has been
completed by molecular studies of the role of
repeated sequences in drug tolerance in [42].
B. Ecology, evolution and cancer in cell popula-
tions
“Nothing in biology makes senses except in
the light of evolution.” (Theodosius Dobzhansky,
1964 [27])
The animal genome (of the host to cancer) is
rich and amenable to adaptation scenarios that,
especially under deadly environmental stress,
may recapitulate salvaging developmental sce-
narios - in particular blockade of differentiation
or dedifferentiation, allowing better adaptabil-
ity but resulting in insufficient cohesion of the
ensemble - that have been abandoned in the
process of the great evolution [45], [46] from
unicellular organisms (aka Protozoa) to coher-
ent Metazoa [23] (aka multicellular organisms).
In cancer populations, enhanced heterogeneity
with enhanced proliferation and poor differenti-
ation results in a high phenotypic or genetic di-
versity of immature proliferating clonal subpop-
ulations, so that drug therapy may be followed,
after initial success, by relapse due to selection
of one or more resistant clones [25].
As regards ecology and evolution, genetics
and epigenetics: ecology is concerned with thriv-
ing or dying of living organisms in populations
in the context of their trophic environment.
Evolution is concerned by the somatic changes,
either inscribed by genetic mutations of base
pairs in the marble of their DNA, or only -
and sometimes geneticists in that case dismiss
the term evolution, preferring adaptation - re-
versibly (however transmissible to the next gen-
erations) modified by silencing or re-expressing
genes by means of grafting methyl or acetyl
radicals on on the base pairs of the DNA or
on the aminoacids that constitute the chromatin
(i.e., histones) around which the DNA is wound.
In the latter case, such evolution is determined
by epigenetic mechanisms, i.e., mechanisms that
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do not change the sequence of the base pairs,
but only locally modify their transcriptional
function. At the level of a same multicellular or-
ganism, such so-called epimutations govern the
succession of events that physiologically result
in cell differentiations.
At this stage, one must clearly distinguish
three different meanings of the words evolution
and differentiation/maturation: 1) at the short-
term time scale of a cancer cell population,
evolution by (plastic) adaptation of phenotype
or by mutations - both phenomena may be
encountered - to a changing environment such
as infusion of an anti-cancer drug [32]; 2) at the
mid-term time scale of a developing animal or
human organism, programmed succession of cell
differentiations, leading from one original cell
to the circa 200-400 different cell types (in the
human case) that constitute us as multicellular
organisms (development): no mutations, only
differentiations (aka maturations), i.e., epige-
netic changes within the same genome until
each cell reaches its completely physiologically
mature state (an example of an ODE model of
differentiation may be found, e.g., in [44]); 3) at
the very long-term (billions of years) time scale
of Darwinian evolution of species, succession of
mutations from protozoa until evolved metazoa.
Epigenetic changes in a cell population are
not rare events and may be fast, operating under
environmental pressure by means of epigenetic
control enzymes (methylases and acetylases,
DNA methyltransferases, etc.), and they are
reversible, however likely less quickly than they
have occurred [88]. It is also likely, and indeed
this has been shown in some cases, that follow-
ing such reversible epigenetic events, rare events
that are mutations (not so rare in the context
of genetic instability that often characterises
cancer cell divisions) stochastically happen, fix-
ing in the DNA an acquired advantage in the
context of a changing environment. Conversely,
mutations in parts of the genome that code for
epigenetic control enzymes may determine epi-
genetic changes, metaphorically representable in
the Waddington epigenetic landscape [45], [46],
[106]. Such genetic to epigenetic modifications
and vice versa are discussed in [14], [36], [37].
Also note that the relationships between ecol-
ogy, evolution and cancer are extensively devel-
oped in the book [102].
C. The atavistic theory of cancer
There has been some debate in the past 20
years about two opposed views of cancer, the
classic one, advocated by P. Nowell [71] states
that cancer starts from a single “renegade”
cell (a cheater), that by a succession of muta-
tions initiates cancer (Somatic Mutation The-
ory, SMT), being followed by strict Darwinian
selection of the fittest, while the less admitted
Tissue Organisational Field Theory (TOFT),
advocated in particular by A. Soto and C. Son-
nenschein [90], contends that cancer is a matter
of deregulated ecosystem, amenable to eradica-
tion by changing the tumour ecosystem. The
atavistic theory of cancer is completely different
from those two, in as much as it relates cancer
to a regression in the billion year-long evolu-
tion of multicellularity. The idea that cancer is
a form of backward evolution from organised
multicellularity toward unicellularity, stalled at
the poorly organised forms of multicellularity
tumours consist of (as cancer cell populations,
escaping the collective control present in delicate
organismic organisations that constitute coher-
ent multicellularity, continuously reinvents the
wheel of multicellularity, starting from scratch
for their own sake) is not new and it has at
least been proposed by T. Boveri in 1929 [7]
and L. Israel in 1996 [47]. However, it has
regained visibility thanks to the documented
and simultaneous studies by physicists P.C.W.
Davies and C.H. Lineweaver [23], [55] and oncol-
ogist M. Vincent [103], [104], followed by various
subsequent studies, constituting a new body
of knowledge [11], [19], [97], [98], [108] under
the name of atavistic theory of cancer. This
theory, or hypothesis, postulates that, although
cancer reinvents the wheel of multicellularity,
it has at its disposal for this task “an ancient
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toolkit of pre-existing adaptations” that makes
it fundamentally differ from classical Darwinian
evolution [23]. In this respect, cancer is clearly
“more an archeoplasm than a neoplasm” (Mark
Vincent [103]).
What is relatively new in this theory, com-
pared with the previously cited ones, is the
idea that an intermediate set of coarse forms
of multicellularity (which they call “Metazoa
1.0”), lacking coherent control of intercellular
- and between cell populations - cooperativ-
ity and proliferation, qualified a “robust toolkit
for the survival , maintenance and propagation
of non-differentiated or weakly-differented cells”
is a safety state to which “Metazoa 2.0” (us,
in particular) revert when our sophisticated
form of multicellularity goes astray in cancer.
Such events are due to failures in control of
evolved cooperativity genes, and this incoher-
ent, chaotic, poorly organised “Metazoa 1.0”
system endows the tissues in which it is installed
with high phenotype adaptability, aka cancer
plasticity, on which tumour development relies.
Such plasticity makes tumour cells in particular
able to exploit for their own sake, plasticity
resulting in resistance to cytotoxic drugs, epige-
netic enzymes that were physiologically designed
to control finely tuned cell differentiations, in
acquired resistance to cancer treatments. This
illuminating view of cancer, according to which
the genes that malfunction are precisely “the
genes of cellular cooperation that evolved with
multicellularity about a billion years ago” (Paul
Davies and Charles Lineweaver [23]), and the
reason of resistance is to be found in ancient,
well preserved, genes of our DNA, is however
quite often not admitted by many biologists
of cancer who strongly believe in the strictly
Darwinian nature of evolution in cancer cell
populations [33], [34], [39], [40], without any
kind of such “genomic memory”.
Compatible with the atavistic hypothesis that
postulates such backward evolution, a possible
scenario suggests that cancer may start with
a local deconstruction of the epigenetic con-
trol of cell differentiation (that is an essential
piece of the coherence of multicellularity, e.g.,
in haematopoiesis, by genes TET2, DNMT3A,
ASXL1), followed by deregulation of cooper-
ativity between cell populations (essential to
division of work in a multicellular organism)
initiated by disruption of transcription factors
responsible for differentiation (e.g., by genes
RUNX1, CEBPα, NPM1) and finally deregula-
tion of the determinants of the strongest and
most ancient bases of multicellularity, prolif-
eration and apoptosis (e.g., by genes FLT3,
KIT, and genes of the RAS pathway). Even
though many cancer biologists are reluctant to
endorse this scenario, biological observations ex-
ist, showing that a scenario of successions of
mutations may be found in fresh blood sam-
ples of patients with acute myeloid leukaemia,
phylogenetically recapitulating such hierarchi-
cally ordered deconstruction of the multicellu-
lar haematopoietic structure, from the finest
(epigenetic) to the coarsest (proliferation and
apoptosis) elements of the construction of mul-
ticellularity [43].
From the point of view of therapeutic appli-
cations, the atavistic theory of cancer has the
consequence that, even though those genes of
cooperativity that are altered in cancer (the
“multicellularity gene toolkit of Metazoa 1.0”)
have taken one billion years of Darwinian evo-
lution to achieve (by ‘tinkering’ [49]) coher-
ent evolved multicellular organisms, they are
nevertheless in finite number and can be sys-
tematically investigated, as has been initiated
in phylostratigraphic studies led by Tomislav
Domazet-Lošo and Diethard Tautz [28], [29].
Such systematic between-species phylogenetic
biocomputer studies should open observation
windows onto altered genes in patients and their
possible correction in the future.
From the point of view of mathematical mod-
elling, the fact that ancient genes of survival
have been developed in the course of evolution
to make individual cells, and later coherently
heterogeneous and nevertheless communicating
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together (failures in intercellular communica-
tions [99], [100], [101] incidentally being also
a possible source of default of cooperativity
in cell populations), and may be conserved as
silent capacities in our genome, only waiting to
be unmasked by epigenetic enzymes [88] put on
the service of survival in highly plastic cancer
cells [107], gives reasonable biological support
to the notion of cell populations structured in
phenotype of survival and of drug resistance.
How such ancient genes (‘cold genes’ [107]) have
been preserved in our genome while serving
in rare and extreme environmental conditions
only is not clear (in principle, genes that are
not expressed are prone to disappear), however
observations reported in [107] propose that an-
cient genes evolve more slowly than younger
ones. Hence, preserved in the genomic memory
as survival genes, revivable in plastic cancer
cell populations (plastic here meaning that they
have easy access to epigenetic enzymes to change
their phenotype under environmental pressure),
their level of expression may offer a basis for
evolvability and reversibility, under environmen-
tal pressure, of continuous phenotypes structur-
ing the heterogeneity (aka biological variability)
of cancer cell populations that is developed in
mathematical models of adaptive cell population
dynamics.
III. Models of adaptive dynamics
A. Models structured in resistance phenotype
The simplest model of a resistance phenotype-
structured cell population may be described by a
nonlocal Lotka-Volterra-like integro-differential
equation, here x ∈ [0, 1] representing a contin-
uous resistance phenotype, from x = 0, total













n(t, x) dx and n(0, x) = n0(x).
Note that this simple integro-differential equation
may, when this makes biological sense, be gen-










n(t, x) + {r(x)− d(x)ρ(t)}n(t, x).
We assume reasonable (L∞) hypotheses on
r and d, and n0 ∈ L1([0, 1]). Phenotype-
dependent functions r and d stand for intrinsic
proliferation rate and intrinsic death rate due
to within-population competition for space and
nutrients, respectively. Note that space is repre-
sented here only in the abstract nonlocal logistic
term d(x)ρ(t). It is nevertheless possible to mix
phenotype and actual Cartesian space variables
to structure the population, as will be shown
later.
One can then prove for the simple integro-
differential model the asymptotic behaviour the-
orem:
Theorem 1. [24], [48], [74]
(i) ρ converges to ρ∞, the smallest value ρ such
that r(x) − d(x)ρ ≤ 0 on [0, 1] (i.e., ρ∞ =
max[0,1] rd).
(ii) The population n(t, ·) concentrates on the
phenotype set
{
x ∈ [0, 1], r(x)− d(x)ρ∞ = 0
}
.
(iii) Furthermore, if this set is reduced to a
singleton x∞, then n(t, ·) ⇀ ρ∞δx∞ in M1(0, 1).
(the measure space M1(0, 1) being the dual
for the supremum norm of the space of continu-
ous real-valued fonctions on [0, 1]; note the Dirac
mass on the RHS, convergence is here meant in
the sense of measures.)
Although in the one-population case, as
stated above, a direct proof of convergence based
on proving that ρ(t) is BV on the half-line,
from which concentration easily follows from
exponential growth, it is interesting to note,
as this argument can be used in the case of
two interacting populations, that a global proof
based on the design of a Lyapunov function gives
at the same time convergence and concentration:
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choosing any measure n∞ on [0, 1] with support
in argmax rd such that∫ 1
0

















w(x) {r(x)−d(x)ρ∞}n(t, x) dx,
which is always nonpositive, tends to zero for
t → ∞, thus making V a Lyapunov function,
and showing at the same time convergence and
concentration.
Indeed, in this expression, the two terms are
nonpositive and their sum tends to zero; the zero
limit of the first one accounts for convergence
of ρ(t), and the zero limit of the second one
accounts for concentration in x (on a zero-
measure set) of lim
t→+∞
n(t, x).
Starting from this simple model, one can gen-
eralise it to the case of two interacting cell pop-
ulations, cancer (nC) and healthy (nH), again
using a nonlocal Lotka-Volterra setting, with
two different drugs, u1, cytotoxic (= cell-killing
drug, towards which resistance evolves according
to the continuous phenotype x ∈ [0, 1]) and u1,



















The environment in the logistic terms is defined
by:
IH(t) = aHH .ρH(t) + aHC .ρC(t),
IC(t) = aCH .ρH(t) + aCC .ρC(t),
with aHH > aHC , aCC > aCH (higher within-








The cytotoxic drug terms, tuned by drug sen-
sitivity functions µC and µH , act as added death
terms to the logistic term, whereas the cyto-
static drug terms act by inhibiting the intrinsic
proliferation rates rC and rH . Functions µC and
µH obviously have to be decreasing functions
of x, and so, less obviously, but representing
a trade-off between survival and proliferation
(“cost of resistance”), have to be rC and rH . As
regards dC and dH , no modelling choice imposes
itself; however, in order to make the function
r
d globally decreasing and thus, in the absence
of drug, obtain its maximum around zero, it
was assumed in this study that it is a non-
decreasing function of x. Biologically, this means
that the more resistant a cell is, the stronger
opposition to its proliferation it encounters in its
own species, cancer or healthy, which is another
way, coherent with the modelling choice made
on rC and rH , to express a cost of resistance.
In this 2-population case, following an ar-
gument by Pierre-Emmanuel Jabin and Gaël
Raoul [48], one can prove, as in the 1-population
case, at the same time convergence and concen-
tration by using a Lyapunov functional of the
form∫
w(x) {n(t, x)− n∞(x)− n∞(x) lnn(t, x)} dx.
We have also in this case the asymptotic
behaviour theorem:
Theorem 2. [81], [83] Assume that u1 and u2
are constant: u1 ≡ ū1, and u2 ≡ ū2. Then,
for any positive initial population of healthy and
of tumour cells, (ρH(t), ρC(t)) converges to the
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equilibrium point (ρ∞H , ρ∞C ), which can be exactly
computed as follows:
Let a1 ≥ 0 and a2 ≥ 0 be the smallest nonnega-
tive real numbers such that
rH(x)
1 + αH ū2
− ū1µH(x) ≤ dH(x)a1 and
rC(x)
1 + αC ū2
− ū1µC(x) ≤ dC(x)a2.
Then (ρ∞H , ρ∞C ) is the unique solution of the
invertible (aHH .aCC > aCH .aHC) system
I∞H = aHHρ∞H + aHCρ∞C = a1,
I∞C = aCHρ∞H + aCCρ∞C = a2.
Let AH ⊂ [0, 1] (resp., AC ⊂ [0, 1]) be the set
of all points x ∈ [0, 1] such that equality holds in









converge respectively to AH and AC as t tends
to +∞.
In [81], this result is complemented with nu-
merical simulations which show the failure of
constant administration of high doses of both
drugs. The theorem explains the phenomenon:
such a strategy makes the cancer cell density
concentration on a very resistant phenotype
near x = 1. Once most of the mass is close to
x = 1, further treatment is hopeless as the tu-
mour has become mostly resistant, and it starts
increasing again after having first decreased.
This can be interpreted as relapse.
Note that numerical studies based on a sim-
ilar model of adaptive dynamics in a reaction-
diffusion version, dealing with the question of
relapse, can be found in [16], [17], [56], [57],
see also [74], [75] for more theoretical consid-
erations.
This result extends to two competitively in-
teracting populations the result of convergence
and concentration for nonlocal Lotka-Volterra
phenotype-structured models previously pub-
lished in [24], [48], [74]. Note that it assumes
the invertibility of the square matrix [aij ] where
i, j ∈ {H,C}.
A natural question then arises: is it possible
to extend this result to N > 2 interacting
populations? This is the object of the study [82],
in which the following N -dimensional nonlocal
Lotka-Volterra system is set, for which one can
look for coexistence of positive steady states








in which x stands for all xi ∈ Xi for simplicity,
each Xi being a compact subset of some





This system generalises to a nonlocal setting
classical Lotka-Volterra models (for 2 popula-
tions in an ODE setting, see, e.g., Britton [8] or
Murray [69]) with ecological cases: mutualistic
if aij > 0 and aji > 0, competitive if aij < 0
and aji < 0 , predator-prey-like if aijaji < 0, for
the interaction matrix A = [aij ]
In [82], to which the reader is sent for more
details, it is proved that a coexistent positive
steady state
ρ∞ = [ρ∞1 , . . . , ρ∞i , . . . , ρ∞N ]t
exists in RN if and only if, setting
I∞ = [I∞1 , . . . , I∞i , . . . , I∞N ]t,





Aρ + I∞ = 0 has a solution ρ∞ ∈ RN . Then,
under some precise conditions on A, it can be
proved, again using the same kind of Lyapunov
function as in [81], that the solution to the
N -dimensional nonlocal Lotka-Volterra system
exists and is globally defined; furthermore, the
solution ρ∞ to the equation Aρ + I∞ = 0 in
RN is then unique and globally asymptotically
stable. As in the 1- and 2-dimensional cases,
a result of concentration in phenotype follows,
with moreover an estimation of the speeds of
convergence and of concentration.
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B. Modelling mutualistic tumour-stroma inter-
actions
Noting that breast and prostate tumours
are accompanied in their stroma by so-called
cancer-associated adipocytes (CAAs) or cancer-
associated fibroblasts (CAFs) [18], [26], [60],
which favour cancer growth, likely by exchang-
ing bidirectional messenger molecules, one can




















for some weight functions ψA and ψC (that in
the absence of known data may be chosen as
simply affine), and some given initial conditions
nA(0, x) = n0A(x), nC(0, y) = n0C(y) for all (x, y)
in [0, 1]2, x standing for transformation towards
a CAA or CAF state in the adipocyte popula-
tion and y standing for strength of malignancy
in the cancer cell population. This model is
studied, theoretically and numerically, in [80] in
its generalised reaction-diffusion-advection form
(see above) with explicit functions and initial
functions n0A, n0C assumed to be Gaussian.
In a setting in which mutualistic interactions
between two cell species, one of them being ini-
tially healthy, but susceptible to become cancer-
ous, namely proliferating haematopoietic stem
cells and early progenitors nh, in the mandatory
presence of the other species ns, supporting
stromal cells, a model closely related to the











This system is completed with initial data
nh(0, x) = nh0(x) ≥ 0, ns(0, y) = ns0(y) ≥ 0.








are the total populations of HSCs and
their supporting stromal cells MSCs, re-
spectively, x representing a malignancy po-
tential in haematopoietic cells and y a










denote an assumed chemical signal (Σh)
from the hematopoietic immature stem
cells (haematopoietic stem cells, HSCs)
to their supporting stroma (mesenchymal
stem cells, MSCs), i.e., “call for support”
and conversely, a trophic message (Σs) from
MSCs to HSCs. The weight functions ψh, ψs
are nonnegative and defined on (a, b) and
(c, d), intervals of the real line.
• The function rh ≥ 0 represents the intrin-
sic (i.e., without contribution from trophic
messages from MSCs) proliferation rate of
HSCs. Assume that rh is non-decreasing,
rh(a) = 0 and rh(b) > 0.
• The function α ≥ 0, satisfying α′ ≤ 0 and
α(b) = 0, is the sensitivity of HSCs to the
trophic messages from supporting cells.
• For the function rs ≥ 0, it is assumed that
r′s(y) ≤ 0. The function β(y) ≥ 0 with
β′(y) ≥ 0 represents the sensitivity of the
stromal cells MSCs to the (call for support)
message coming from HSCs.
Some examples for rh, α are given by rh =
r∗h(x − a) or rh = r∗h(x − a)2, α(x) = α∗(b − x)
with positive constants r∗h, α∗, ψs(y) = y and
ψh(x) = x.
The reader is sent to [70] for a detailed study
of this model. In particular, theoretical condi-
tions for extinction, invasion or possible stable
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coexistence of a leukaemic clone emerging in an
initial healthy HSC population together with a
maintained healthy fraction of it, with numerical
simulations, are given in this study. They are
related to convexity or concavity properties of
functions of the model describing proliferation
of the population, rh and α, the same kind
of evolution being possible in the stromal cell
population.
C. Models structured in phenotype and space
Although purely space-structured models lack
the necessary heterogeneity in phenotype to
take into account continuous evolution towards
drug-induced drug resistance, purely phenotype-
structured models lack the possibility to exam-
ine possible heterogeneities due to extension of
tumours in Cartesian space, in particular due
to diffusion of molecules (anticancer drugs and
nutrients) in the medium. Hence, provided that
something is known of the geometry of the space
occupied by a cancer cell population, and this
is indeed the case with initial tumours that
spontaneously thrive in spheroids, mixing space
with phenotype to structure a model of a cancer
cell population under drug exposure, to study its
behaviour with respect to drug resistance, is a
natural way to proceed.
Relying on modelling principles developed
in [52], [58], integrated in spheroid-like space,
such a model is studied in [59]:
































with zero Neumann conditions at r = 0
(spheroid centre) coming from radial symmetry
and Dirichlet boundary conditions at r = 1
(spheroid rim):
s(t, r = 1) = s1, ∂rs(t, r = 0) = 0,
c1,2(t, r = 1) = C1,2(t), ∂rc1,2(t, r = 0) = 0,
where:
• The function p(x) is the intrinsic (i.e., in-
dependently of cell death) proliferation rate of
cells expressing resistance level x due to the
consumption of resources. The factor
1
1 + µ2c2(t, r)
mimics the effects of cytostatic drugs, which act
by slowing down cellular proliferation, rather
than by killing cells. The parameter µ2 models
the average cell sensitivity to these drugs.
• The function d(x) models the death rate of
cells with resistance level x due to the competi-
tion for space and resources with the other cells.
• The function µ1(x) denotes the destruction
rate of cells due to the consumption of cytotoxic
drugs, whose effects are here summed up directly
on mortality.
• Parameters σs and σc model, respectively,
the diffusion constants of nutrients and cyto-
toxic/cytostatic drugs.
• Parameters γs and γc represent the decay
rate of nutrients and cytotoxic/cytostatic drugs,
respectively.




x, %(t, r), c1,2(t, r), s(t, r)
)
n(t,r,x),
in order to highlight the role played by the net








1 + µ2c2(t, r)
s(t, r)− d(x)%(t, r)− µ1(x)c1(t, r).
The following considerations and hypotheses are
assumed to hold:
•With the aim of translating into mathematical
terms the idea that expressing cytotoxic re-
sistant phenotype implies resource reallocation
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(‘cost of resistance’, i.e., redistribution of ener-
getic resources from proliferation-oriented tasks
toward development and maintenance of drug
resistance mechanism, such as higher expression
or activity of ABC transporters in individual
cells), p is assumed to be decreasing
p(·) > 0, p′(·) < 0.
As regards function d, one can note that in
this study [59], the advocated modelling choice
(d′(·)< 0) is the opposite of the one that was
made in [58], a study nevertheless published
by the same authors. In [58], the underlying
biological reason is possibly that ‘the more re-
sistant a cell is, the stronger opposition to its
proliferation it encounters in its own species,
cancer or healthy, which is another way, coherent
with the modelling choice made on rC and rH ,
to express a cost of resistance’ (see this argu-
ment developed above in Subsection III-A). As
a matter of fact, the simulations shown in this
study [59] always use a constant value for d, and,
contrary to [58], no theorem is proposed to the
reader of [59], which should induce to actually
choose d′(·) ≥ 0.
• The effects of resistance to cytotoxic therapies
are modeled by the obvious condition that the
drug sensitivity function µ1 is non-increasing:
µ1(·) > 0, µ′1(·) ≤ 0.
The interesting results of this model consist of
simulations, illustrated by figures to which the
interested reader is referred.
D. Models structured in cell-functional variables
A puzzling observation on an in-vitro ag-
gressive cancer cell culture (PC9, a variant of
NSCLC cells) exposed to high doses of anti-
cancer drug, experiment reported in [88], is that:
1) even though 99.7% of cells quickly die when
exposed to the drug, sparse and tiny subpopula-
tions (0.3%) survive, named drug-tolerant per-
sisters (DTPs), and for some time just survive,
exposed to the same very high concentration of
drug; 2) after some time (not precisely defined
in the paper), these surviving cells change their
phenotype as expressed by membrane markers,
and proliferate again, then named drug-tolerant
expanded persisters (DTEPs), unabashed in the
maintained high drug dose; 3) when the drug
is washed out from the cell culture, the cell
population reverts to initial drug sensitivity, and
such resensitisation occurs ten times more slowly
at the DTEP stage than at the DTP stage; 4)
if the cell culture is exposed to an inhibitor of
the epigenetic enzyme KDM5A together with
the drug, be it at the DTP or DTEP stage,
DTPs - or DTEPs - die. Such clearly epigenetic
and completely reversible mode of resistance,
developed in two stages, called for designing a
cell population dynamic model structured, not
as previously, monotonically in drug resistance
gene expression level, but in phenotypes linked
to the cell fate, which in cell populations al-
ways may be reduced to proliferation, death
or differentiation (senescence being a version of
delayed death). In the modelling and numerical
study [13], 2 phenotypes are thus chosen to take
into account the cell population heterogeneity
relevant for the experiment: survival potential
under extreme environmental conditions (called
by ecology theoreticians viability), x, and pro-
liferation potential (called fecundity), y. The
resulting model is described by the reaction-
diffusion-advection equation, that describes the
behaviour of a very plastic cell population under
exposure to a high dose of anticancer drug:
∂n
∂t
(x, y, t) + ∂
∂y
(


























and d(x, c) = c(b1 + b2(1− x)) + b3
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n(x, y, t) dx dy
occurs in p as a logistic environment lim-
iting term (availability of space and nutri-
ents).
• The drift term w.r.t. proliferation po-
tential y represents possible (if v 6=
0) ‘Lamarckian-like’, epigenetic and re-
versible, adaptation from PC9s to DTPs;
switching from v ≥ 0 to v = 0 here
means switching from a possible adaptation
scenario to a strictly Darwinian one (it is
biologically impossible to decide between
the two scenarios).
• v(x, c(t); v̄) = −v̄c(t)H(x∗ − x) where t 7→
c(t) is the drug infusion function, and x∗ is
a fixed viability threshold.
• No-flux boundary conditions.
Of note, another, individual-based, model
(IBM) yielding the same simulation results (no
theorem) is proposed in a complementary way
to the interested reader, sent to [13].
The simulation results firstly show total
reversibility to drug sensitivity when the drug
is withdrawn, and also allow to study the
evolution of the two phenotypes in the absence
of drug, under drug exposure, and when the
drug is withdrawn. Furthermore, the model was
put at stake by asking 3 questions:
Q1. Is non-genetic instability (Laplacian term)
crucial for the emergence of DTEPs?
Q2. What can we expect if the drug dose is
low?
Q3. Could genetic mutations, i.e., an integral
term involving a kernel with small
support, to replace both adapted drift
(advection) and non-genetic instability
(diffusion), yield similar dynamics?
Consider c(·) = constant and two scenarios:
(i) (‘Lamarckian’ scenario (A): the outlaw)
Only PC9s initially, adaptation present
(v 6= 0)
(ii) (‘Darwinian’ scenario (B): the dogma)
PC9s and few DTPs initially, no adaptation
(v = 0)
To make a long story short [13],
• Q1. Always yes! Whatever the scenario.
• Q2. Low doses result in DTEPs, but no
DTPs.
• Q3. Never! Whatever the scenario.
Can such cell-functional models be used to
actually manage drug resistance in the clinic?
An idea would be to counter the plastic adap-
tation that cancer cell populations show in the
presence of high doses of drugs by infusing at
the same time as cytotoxic drugs inhibitors of
epigenetic enzymes such as KDM5A in [88].
However, even though epigenetic drugs are the
object of active research in the pharmaceutic in-
dustry [89], the importance of epigenetic control
of physiological processes (all differentiation is
epigenetic!) and the role of impaired epigenetic
controls in impaired cell differentiation, which is
a characteristic of cancer, has been stressed [31]
makes them delicate to manage in the clinic so
far.
IV. Optimisation and optimal control
A. ODE models and their optimal control in
cancer
To go beyond the administration of constant
doses, one is led to let drug infusion rates vary
in time and try to find the best such rates to
minimise a given criterion, such as the number
of cancer cells at the end of a given time-window.
This is the purpose of the mathematical field of
optimisation (see, e.g., in another framework [5],
[20]) and optimal control, with all its available
theoretical and numerical tools.
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At this stage, it is noteworthy that the dis-
cretisation of the phenotype-structured PDE
models introduced so far leads to ODEs, usually
of Lotka-Volterra type. To illustrate the idea, let









If one discretises the phenotype space into
Nx + 1 equidistant phenotypes through xi =
i∆x, ∆x = 1Nx the above equation is approxi-







yi(t), i = 0, . . . , N
where yi(t) ≈ ∆xn(t, xi) and ρ(t) =
∑N
j=0 yi(t).
This remark is general and applies to the
numerical simulation of phenotype-structured
PDE models (this is nothing but a semi-
discretisation of the corresponding PDE). This
point of view also makes the link between
ODE models where resistance is represented
by a binary variable, or more generally, a dis-
crete variable. With a coarser discretisation,
the ODE model has few equations and is more
amenable to parameter identification, quick nu-
merical simulation, but is also less accurate in
representing resistance.
When it comes to optimal control, ODE mod-
els with a discrete representation of resistance
have long been studied, either theoretically or
numerically [91], [22], [50]. This is one aspect of
the rich literature on optimal control for cancer
modelling, see the reference book [86]. Note that
these ODE models can be made richer, as they
may additionally model healthy cells, cells in
different compartments of the cell cycle, immune
cells, etc.
Independently of the number of equations,
the investigation of the optimal control problem
typically leads to optimal strategies being the
concatenation of bang-bang and singular arcs.
Bang-bang arcs correspond to drugs being ei-
ther given at the maximum tolerated dose or
not at all, whereas singular arcs correspond to
intermediate doses which can be computed in
feedback form from the yi’s. These results are
obtained either numerically, or theoretically by
applying the Pontryagin Maximum Principle,
possibly with higher order criteria (such as the
Legendre-Clebsch criterion) and/or with geo-
metric optimal control techniques.
The usual clinical practice is to use maximum
tolerated doses, a strategy which has been called
into question as it can lead to an initial drop
in tumour size before regrowth due to acquired
resistance [25]. This corresponds to bang-bang
controls. Instead, alternative and more recent
strategies advocate for the infusion of interme-
diate doses [35], [73], [93].
Thus, as explained in [53], understanding
whether the optimal controls do contain sin-
gular arcs is of paramount importance, and
might depend from the parameters governing
the cost. The recent work [12], where resistance
is modelled to be binary, also features parameter
regions leading to singular arcs which follow a
first arc with maximum tolerated doses.
This naturally poses the question of opti-
mal scheduling for PDE models of resistance.
The corresponding optimal control problems are
then significantly harder to solve. Numerically,
this is because a fine discretisation leads to
computationally demanding algorithms. Theo-
retically, as is already the case for a high dimen-
sional ODE, it becomes more difficult to obtain
precise results on the optimal control strategy,
even from an (infinite-dimensional) Pontryagin
Maximum Principle.
B. Optimal control of phenotype-structured PDE
models
These difficulties might explain why there
are up to date few optimal control results on
phenotype-structured PDEs for resistance. Most
studies are restricted to constant doses and the
optimisation is then performed on the resulting
scalar parameters. This can be done by nu-
merical investigation of the parameter space as
in [16], [58] or theoretically for cases in which
explicit solutions are available [3]. Other non-
constant infusion strategies mimicking popular
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protocols are sometimes also tested in the afore-
mentioned works. Finally, in [3], restriction to
Gaussian solutions allows the authors to reduce
the PDE to a system of three ODEs (for the
total mass, the mean and the standard devia-
tion). All these studies conclude that the con-
tinuous administration of maximum tolerated
doses might lead to relapse, and that alternative
strategies with lower infusion of drugs might be
preferable.
There is, up to our knowledge, very little
work in the direction of tackling a full optimal
control problem for the phenotype-structured
PDEs models, without such simplifications as
above. The two works we are aware of are [72]
and [81], both concerned with the model (1)
(see Section III-A). In [72], the model is more
complex since genetic instability is introduced in
the PDE, modelled by diffusion terms. The goal
is to minimise the total number of cancer cells
ρC(T ), and the overall model is complemented
with the constraints
• maximum tolerated doses:
0 ≤ u1(t) ≤ umax1 , 0 ≤ u2(t) ≤ umax2 ,
• control of the tumour size:
ρH(t)
ρH(t) + ρC(t)
≥ θHC , (2)
• control of the toxic side-effects:
ρH(t) ≥ θHρH(0), (3)
where 0 < θHC , θH < 1.
In order to solve the problem numerically,
the approach consists in discretising the whole
problem in phenotype and time, thus using a
so-called direct method in numerical optimal
control [96]. This is equivalent to discretising in
time an ODE system which has as many equa-
tions as there are discretised phenotypes. The
optimal control problem then becomes a high
finite-dimensional optimisation problem, which
can be handled, for example, by interior point
methods.
As is common to most numerical optimisation
problems, the biggest difficulty lies in choosing
the initial guess for the algorithm. The approach
of [81] is to solve the optimisation problem
with a very coarse discretisation (few unknowns)
before scaling the problem up progressively to
a fine discretisation. For the generalised model
with mutations, such a strategy fails because of
the computational cost of Laplacians.
To circumvent this, the numerical strategy
introduced in [72] is to simplify the PDEs by
setting some coefficients to zero, so that the
resulting optimal control problem can be solved
by a Pontryagin Maximum Principle. Although
this problem is non-realistic from the applica-
tive a point of view, it provides an excellent
starting point for a homotopy procedure which
allows to go all the way back to the original
more complicated problem, with a very accurate
discretisation.
An optimal strategy clearly emerges from
these two works, when the initial tumour is
heterogeneous (as a result of a first standard
administration of cytotoxic drugs). The idea
is to let the tumour density evolve to a sen-
sitive phenotype by using no cytotoxic drugs
and intermediate (constant) doses of cytostatic
drugs for a long phase, during which the con-
straint on tumour size saturates. Only then one
takes profit of a sensitive tumour by using the
maximum tolerated doses, up until the side-
effects constraint saturates. It is then possible
to further reduce the tumour size by lowering
the cytotoxic dosage.
The asymptotic analysis comes in handy in
understanding the optimality of such a strategy:
the first long phase leads to the convergence of
the cancer cell density onto a Dirac mass located
on a sensitive phenotype (or a smoothed version
of such a Dirac mass when there is a diffusion
term). This property allows the authors of [81]
to perform a theoretical study of the optimal
control problem in a reduced control set where
the controls are forced to take constant values
during a first long phase. The strategy obtained
numerically is then proved to be optimal in a
theorem, informally given below.
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Theorem 3. [81]
When the final time T is large, the optimal
solution is such that
1) at the end of the first phase, the density
of cancer cells has concentrated on a sensitive
phenotype,
2) the optimal strategy is then the concatenation
of three arcs
• an arc with saturation of the constraint on
ρH
ρH+ρC .
• a free arc with maximum tolerated doses,
namely u1 = umax1 and u2 = umax2 ,
• an arc with saturation of the constraint on
ρH and u2 = umax2 .
We insist that this result is proved only in
the absence of diffusion. The proof relies on the
fact that Dirac mass concentration at the end
of the first phase allows to replace the PDE
system by an 2x2 ODE system, up to an error
becoming arbitrarily small as the length of the
phase increases. The resulting optimal control
problem can then be handled with a Pontryagin
Maximum Principle with state constraints.
C. Future prospects in optimal control
Applying the strategy advocated in [72], [81]
requires thinking it in a quasi-periodic manner,
and as a strategy relevant after the traditional
admnistration of the first dose, which usually
induces resistance. The idea would then be to
alternate between:
1. a long phase with cytostatic doses and no
cytotoxic doses (a drug holiday) to resensi-
tise the tumour,
2. a short phase with maximum tolerated
doses until the toxicity is considered to have
reached its limit, with a possible subsequent
switch in dose for the cytotoxic drugs to
keep diminishing the tumour size.
Such a protocol requires to assess the level of
resistance in order to decide when to switch from
1. to 2. and determine when damage to healthy
tissue justifies switching back to 1. A major
difficulty is of course the scarce availability of
biological markers, which critically depends on
each particular cancer. For instance, in prostate
cancer, a regrowth of the plasmatic level of PSA,
routinely available to clinical measures for quite
a long time, after some stagnation time under
treatment may indicate the emergence of resis-
tance. In the same way, for colorectal cancer,
it has been advocated that circulating tumoral
DNA detection may be used for clinical manage-
ment [54], and the same is true of circulating tu-
mour cells [10]; however these techniques are far
from being clinical routine. As regards damages
to healthy tissue, they are numerous (e.g., for
5-FU and other cytotoxic drugs, classical hand-
foot syndrome, mouth sores, neutropenia, that
often lead to treatment interruption), depending
on each molecule and most of all on the evalu-
ation of their severity by the oncologist in the
clinic, given the health status of the patient un-
der treatment (in the case of laboratory animals,
weight loss is a common indicator of toxicity).
Taking advantage of the models introduced
in Section III, there are several directions for
analysing such types of optimal control but in
a slighly different or generalised setting. This
would both test the robustness of the strategy
presented above, and possibly lead to alternative
ones depending on the context.
The addition of an advection term would
help modulate the speed at which emergence
and resensitisation occur. Modelling how such
terms would depend (or not) on a given drug
is already an issue. However, it is likely that
the addition of such a term will not jeopardise
the numerical computation of optimal controls
with direct methods refined with homotopies.
Of course, considering higher-dimensional phe-
notype variables or adding a space variable will
inevitably lead to an explosion in complexity.
This is why the numerical optimal control
of phenotype-structured PDEs will benefit from
state-of-the-art methods in that field, which in
turn highly rests on the quality of optimisa-
tion solvers. In other words, expert numerical
methods will undoubtedly be at the core of
any attempt at solving these complex infinite-
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dimensional problems.
The theoretical aspects are more exploratory.
Even for the integro-differential system of [81],
the optimal control had to be solved in a re-
stricted class of controls, and a complete under-
standing of the interplay between concentration
phenomena and optimal control is yet to emerge.
With few tools available for the control and op-
timal control of non-local PDEs (an active area
of research), a theoretical analysis of optimal
controls of PDE structured models is at this
stage a real hurdle.
V. Open and challenging questions
A. Conflicting phenotypes and multicellularity
The question of emergence of drug-resistant
clones in a possibly totally genetically homoge-
neous cancer cell population (as is likely the case
of the observations reported in [76], [77], [88])
under environmental pressure, here drug expo-
sure, is related to the emergence of multicellu-
larity in unicellular organisms. This question has
been the object of many studies by evolutionary
biologists [1], [63], [65], [66], [67], and they
hypothesise that, confronted with a challeng-
ing, possibly deadly, environmental pressure, an
already existing, without specialisation, multi-
cellular aggregate (this had to occur after the
beginning of massive oxygenation of the ocean
and atmosphere, about one billion years ago, as,
to stick together, cells need some glue of collagen
family, which is synthesised only in the presence
of free oxygen [94], [95]) had to specialise to
survive. The proposed paradigmatic scenario is
in [63], [65] the conflict between proliferation - or
fecundity, with adhesivity, to maintain against
predators a colony of replicating cells on a good
environmental trophic niche - and motility - to
make the aggregate able to change its location,
to leave for a more favourable one when re-
sources are become scarce or when predators
are threatening. The solution of such conflict
is found in specialisation in two phenotypes,
later to be refined, likely by bifurcations in
more than two if the environmental pressure is
diversified. This question has been tackled by
Yannick Viossat together with Richard Michod
in a simple setting [67], from which one finds
that according to the convexity or concavity of
a level set on which an optimum of fitness is
to be found, there may be coexistence of two
phenotypes or predominance of a single one.
Such a situation is encountered in an adaptive
dynamics framework in [70] (see Section III-B)
for the possible invasion, or coexistence with
healthy cells, of a leukaemic cell clone. However,
how to model such specialisation and cooper-
ativity in general, or in the particular case of
viability vs. fecundity for cancer cells under drug
pressure, still escapes our efforts.
B. Coherence in an organism and its control
The question of coherence - and of within-
and between-tissue cohesion - of a whole mul-
ticellular organism with so many diverse and
specialised subpopulations is seldom posed, and
except in [78], it is generally ignored. Matej
Plankar and co-authors ask the main question
that is so often dodged when speaking of cancer
as a developmental disorder: ‘What exactly is
disorganised that was previously organised?’ and
they propose that the biophysical base of such
coherence resides in the coherence, in the phys-
ical sense, of oscillatory signals between cells
that might be of electromagnetic or quantum
nature, transporting energy and information,
that could originate from, or be transmitted by,
microtubules working like antennas, to - likely
too vaguely and unfaithfully - sum up their
hypotheses. How are such signals synchronised?
Is there a forcing signal originating from an
organisational centre, or is it based on some sort
of multilevel system of phase-locked loops?
A possible candidate for such an organising
system is the circadian system, that is made of
circadian clocks [84], [87], existing in all nucle-
ated cells (and even, so it seems, in red blood
cells by different mechanisms), and that consist
of oscillators based on gene networks that exist
in all, at least, animal cells (but have also been
individuated in some plants). Such oscillators
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have firstly been evidenced in fruitflies [51], and
later in all mammals [105] where they have been
searched for. They have the general property to
be daily reset by the sun (or by routine social
activities when the sun does not shine its rays),
and they date back to a very ancient past of our
planet. There exists a central control centre, the
circadian pacemaker located in the suprachias-
matic nuclei of the hypothalamus in mammals,
that receives synchronising electric signals from
external light via the retinohypothalamic tract
and physiologically sends synchronising mes-
sages to all peripheral cells via hormones and the
autonomic nervous system. The activity of the
central circadian pacemaker, that is in particular
reflected by body temperature oscillations and
by oscillations of corticosteroids in the surrenal
gland, is known to be disrupted in cancer [85],
and this all the more so as cancer is more
advanced. Although the authors of [78] do not
mention this synchronising system, it is coherent
with their view. Is the circadian the synchronis-
ing system? or is it a dubbing system, under
the dependence of an electromagnetic or quan-
tum signalling system advocated in [78]? More
hidden than the circadian system, could some
organising coded plan, progressively established
together with the immune system in the devel-
opment of multicellularity, be the glue and con-
trol on which all Metazoan between- and within-
tissue coherence relies? In other words, could
there exist a set of genes, already present in early
Metazoa, likely related to epigenetic control,
that would on the one hand define, in a MHC
(major histocompatibility complex)-like way, in
its fixed part a species and, at the individual
level, an individual within a species, and on the
other hand a variable part within a species that
would give rise to the different cell phenotypes
that make a coherent multicellular organism
(in limited number, 200 to 400 cell types or
so, from enterocytes to neurons in a Human).
Would this be the case, then one could imagine
that tumours - as Metazoa 1.0, according to
the atavistic hypothesis of cancer - might have
developed a sort of primitive, failed, immune re-
sponse system whose main failure and difference
with respect to the host normal immune system
would be a strong tolerance to plasticity, i.e.,
to lack of belonging to a well-differentiated cell
class. In the metaphoric Waddingtonian view,
this would imply an ablated, flattened epigenetic
landscape, with plenty of room for dediffer-
entiation and transdifferentiation between cell
phenotypes. Could such flattened Waddington’s
epigenetic barriers in return be interpreted in
terms of undecided, empty, spins borne on cell
antigens that should normally, to avoid recogni-
tion as foe by antigen presenting cells, be coded
as either 1 (differentiated) or 0 (open to further
differentiation in a well-defined cell fate), but
not blank? Some support to these speculations
may be found in a study dedicated to the origin
of the Metazoan immune system [68].
C. Intra-tumour cooperativity, plasticity, bet
hedging
If tumours, as Metazoa 1.0, have developed
some internal cooperativity that makes them
able to survive as a whole to cytotoxic stress
and to friend-or-foe recognition by the immune
system, what does such cooperativity consist of?
Experimental evidence exists that such cooper-
ativity exists [21], [79], [92] and is necessary for
a tumour to thrive, while some studies focus
on evidencing tumour genetic or only pheno-
typic heterogeneity [61], [62] without necessarily
proposing a rationale for such heterogeneity.
However, as pointed by Mark Vincent, “Hetero-
geneity, even though it might in some superficial
way, ‘explain’ differential drug sensitivity, is not
in itself an explanation of cancer; rather, it
is the heterogeneity itself that requires explana-
tion.” [104]. Indeed, focusing only on drug resis-
tance, we might satisfy ourselves with the plain
observation of tumour heterogeneity to explain
the variety of drug resistance mechanisms and
why it is so uneasy to eradicate cancer. But try-
ing to understand its determinants is more diffi-
cult. Leaving aside the obvious fact that spatial
isolation of cells inside a tumour may lead under
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different forms of environmental pressure to dif-
ferent (phenotypically or genetically) clones that
may have nothing to do with cooperativity, we
may wonder why different phenotypes may be
found in the same spatial niche. To begin with,
does cooperativity exist with a fixed repartition
of phenotypes inducing some division of labour
in a tumour, or is it not a transient state that
is observed only when a cancer cell population
is put at stake under cellular stress?... Or in
artificial lab conditions [21], [79], [92]?
Can we consider that no actual cooperativity,
in the sense of division of labour in an integrated
structure, exists within a cancer cell population,
all the more so as cell differentiations are im-
paired in cancer, but that plasticity of cancer
cells (and not only of cancer populations) is
so high - within a preestablished Metazoa 1.0
plan, i.e., it is not infinite, but takes advan-
tage of many, but finitely many, stress response
mechanisms inscribed in their genome and easily
reactivatable - that tumours can react to deadly
insults by different resistance mechanisms, the
simplest one being enhanced proliferation out
of control, making them winners in all (known
to their genome) cases? The sole idea of cancer
cooperativity should be examined with care, if
one admits that cancer cells are fundamentally
cheaters, or otherwise said, defectors in the
evolutionary game of multicellularity [2]. How-
ever, primitive Metazoa, such as sponges [68]
or algae show some cooperativity, in particular
as regards immunity to invasion by pathogens.
Have successful tumours regressed in evolution
at an earlier stage than sponges? Likely yes, as
multicellularity in sponges is well controlled.
Following the theme of cancer cell plastic-
ity, an interesting notion has recently emerged,
the so-called bet hedging fail-safe strategy of
cancer cell populations [9], [41]. According to
this hypothesis, cancer cells - or cancer cell
populations - are so plastic that they can adapt
their phenotypes to sustain different insults in-
volving critical cell stress by developing differ-
ent adapted subpopulations. It has also been
observed that some cancer cells may express
very ancient genes (so-called ‘cold genes’, i.e.,
that are conserved throughout evolution, being
protected from evolution due to their essential
role in facing unpredictable, but already met in a
remote past of evolution, deadly insults) in case
of exposure to chemotherapies [107]. One could
speculate that some sentinel cells, expressing
these ‘cold genes’, might send various resistance
messages to other cells, or that they could them-
selves, being extremely plastic, differentiate into
diverse categories of cell subpopulations, each
one developing one of the resistance mechanisms
elaborated in the course of evolution from a
protozoan state, and then sheer darwinian se-
lection would prevail. Whether cells themselves
are plastic and can adapt in a sort of Lamar-
ckian (necessarily epigenetic) way or only cell
populations are plastic, constituted by preexist-
ing (prior to any insult) genetically well-defined
subpopulations is not easy to decide, and in [13],
both scenarios were challenged by a reaction-
diffusion-advection model (see Section III-D).
However, the very fact that cell differentiations
are always - to some extent - impaired in can-
cer cells, the fact that inhibitors of epigenetic
enzymes have been shown in some cases to an-
nihilate drug resistance in very aggressive forms
of cancer (NSCLC cells in culture in [88]) induce
us to propose plasticity as a distinctive and
continuous trait of cancer cells. With respect to
the class of cell-functional models proposed in
Section III-D, i.e., structured in the conflicting
continuous traits named viability (x, potential of
survival in extreme conditions, opposed to apop-
tosis) and fecundity (y, proliferation potential),
one could then add a plasticity trait (θ, opposed
to differentiation), characterising, together with
the first two, each cell in its relevant variability
in a heterogeneous cancer cell population (which
would not give an explanation of such hetero-
geneity, but might help understand its evolution
under cellular stress).
A general class of cell population adaptive
dynamics models that would be structured in
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(x, y, θ) could then, following an idea popu-
larised in [6] for the so-called cane toad equation
(that describes the invasion of cane toads in
Australia by using an equation than cannot be
of the classical reaction-diffusion type yielding
travelling waves), be described by
nt +∇ · {V (x, y, θ,D)n}
= α(θ)nxx + β(θ)nyy + γ(θ)nθθ
+n
{




where r(x, y, θ) is the intrinsic (i.e., in the
absence of any limitation) growth rate of the
population, µ is an added death term due to the
drug dose D, condition C(x, y) ≤ K represents
an environmental constraint, V an optional ad-
vection function standing for abrupt modifica-
tions of the environment (such as the major cell
stress-inducing delivery of high doses of drugs




n(x, y, θ, t) dx dy dθ
is the total cell population at time t, put as
usual in Lotka-Volterra settings in a logistic
position to represent competition, e.g., for nu-
trients, hence growth limitation, within the cell
population.
How such class of models might lead to repre-
sent the emergence of different cell subpopula-
tions under environmental pressure is still work
underway.
VI. Conclusion
In this review of models of adaptive dynam-
ics dedicated to represent, analyse and control
drug-induced drug resistance in cancer, we have
firstly proposed a brief description of the biolog-
ical background of cancer evolution, describing
in particular the atavistic hypothesis of cancer,
which to our meaning illuminates the scenery of
the cancer disease, with more and more observa-
tion facts to support it. Then (neglecting clas-
sical compartmental ODE models that cannot
claim to represent adaptive phenomena), we pre-
sented different cell population dynamics mod-
els that belong to the mathematical category
of adaptive dynamics, i.e., integro-differential
or partial differential equations structured by
continuous traits describing the heterogeneity
of cancer cell populations and their evolution
under drug exposure. In a third part, we showed
how optimal control methods can be applied to
such equations of adaptive dynamics and used
to design theoretical optimal therapeutic control
strategies. Such strategies, even though methods
for the identification of the parameters and
functions of the models still remain to be found,
are amenable to predict qualitative behaviour of
cancer cell populations under optimised time-
scheduled drug exposure. Finally, we presented
some challenging questions, addressed to evolu-
tionary biologists and ecologists of cancer, to on-
cologists, and to mathematicians to accurately
represent, analyse and control the behaviour of
cancer cell populations.
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